Mesoblast plans to file a BLA for Revascor by year-end after aligning with FDA on trial design, potency assays, and ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Heart attack survival odds have dramatically improved over the past 5 decades, but more people are dying from chronic cardiac ...

High levels of bad cholesterol can cause plaque to build up on the walls of your arteries, reducing blood flow and increasing ...

Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items ...

Researchers at UT Arlington have discovered a key enzyme, IDO1, that when blocked, helps immune cells regain their ability to properly process cholesterol—something that breaks down during ...

A major new study has added to a growing body of research highlighting the health risks associated with marijuana ...

Why heart attacks are striking young people A top heart doctor has revealed the insidious supplements and capsules that could ...

As the UK continues to bask in a heatwave, people are being warned to take extra care in the sun if they are on certain ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone. Ozempic for blood sugar control and Wegovy for weight loss both use different ...

Dr Trehan, India’s top cardiologist and Chairman of Medanta, states that there is no conclusive scientific evidence linking ...